Given the important roles of PARP1 in transcription regulation (Kraus and Hottiger 2013), gene expression profiles from ovarian and breast cancer cell lines with known sensitivity to olaparib and rucaparib were used to derive a transcriptional algorithm that can predict sensitivity to PARP inhibitors (McGrail et al. 2017). This evidence concerns the gene PARP1 and breast cancer.